184177-81-9

Basic information

• Product Name: PHENYL {4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYL}CARBAMATE
• Synonyms: PHENYL {4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYL}CARBAMATE;[4-[4-(4-Hydroxyphenyl)-1-piperazinyl]phenyl]carbamic acid phenyl ester;CarbaMic acid, [4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-, phenyl ester (9CI);Posaconazole Impurity 14;Phenyl (4-(4-(4-hydroxyphenyl);phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate;4-(4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL)PHENYL CARBAMATE;Posaconazole Impurity 56
• CAS NO: 184177-81-9
• Molecular Formula: C₂₃H₂₃N₃O₃
• Molecular Weight: 389.46
• Mol File: 184177-81-9.mol

Chemical Properties

• Boiling Point: 603.9°C at 760 mmHg
• Flash Point: 319°C
• Appearance: /
• Density: 1.296
• Vapor Pressure: 3.52E-15mmHg at 25°C
• Refractive Index: 1.67
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.18±0.30(Predicted)
• CAS DataBase Reference: PHENYL {4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYL}CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: PHENYL {4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYL}CARBAMATE(184177-81-9)
• EPA Substance Registry System: PHENYL {4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYL}CARBAMATE(184177-81-9)

Safety Data

• Hazardous Substances Data: 184177-81-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PHENYL 4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYLCARBAMATE is used as a pharmaceutical intermediate for the synthesis of various drugs. Its complex structure allows it to serve as a key component in the development of new medications, potentially contributing to the treatment of various medical conditions.
Used in Antifungal Applications:
PHENYL 4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYLCARBAMATE is identified as an impurity of Posaconazole (P689600), an orally active antifungal triazole. Posaconazole is effective against a wide range of fungal infections, and the presence of this carbamate compound may influence the drug's overall efficacy and safety profile. As an impurity, it is essential to monitor and control its levels in the final drug product to ensure optimal therapeutic outcomes and minimize potential side effects.

InChI:InChI=1/C23H23N3O3/c27-21-12-10-20(11-13-21)26-16-14-25(15-17-26)19-8-6-18(7-9-19)24-23(28)29-22-4-2-1-3-5-22/h1-13,27H,14-17H2,(H,24,28)

Upstream product

• 1885-14-9 phenyl chloroformate 
• 74853-08-0 1-(4-aminophenyl)-4-(4-hydroxyphenyl)piperazine 
• 123-30-8 4-amino-phenol 

Downstream Products

• 184177-83-1 2-[(1S,2S)-1-ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-3H-1,2,4-triazol-3-one 
• 170985-86-1 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-1H-1,2,4-triazol-5(4H)-one 
• 171228-49-2 posaconazote 
• 211627-35-9 2,4-dihydro-2-[(1S,2S)-2-hydroxy-1-methylpropyl]-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one 
• 148626-66-8 2S,4R,2'S,3'S hydroxy itraconazole 
• 1197458-94-8 acetic acid 4-[4-(4-phenoxycarbonylamino-phenyl)-piperazin-1-yl]-phenyl ester 
• 106461-41-0 (-)-(R)-2,4dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol 3-one 

Relevant articles and documents

Preparation method of 4-[4-[4-(4-hydroxyphenyl) piperazine-1-yl] phenyl] phenyl carbamate

The invention discloses a preparation method of 4-[4-[4-(4-hydroxyphenyl) piperazine-1-yl] phenyl] phenyl carbamate, which comprises the following steps: by taking 4-hydroxyaniline as a raw material, carrying out ring closing on the 4-hydroxyaniline and dichloroethylamine hydrochloride to synthesize 1-(4-hydroxyphenyl) piperazine with the purity of 95A% and the correction yield of 80%; 4-nitrochlorobenzene and the prepared 1-(4-hydroxyphenyl) piperazine are coupled to synthesize 4-(4-(4-nitrophenyl)-1-piperazinyl) phenol, the purity is 93 A%, and the correction yield is 88%; then carrying out nitro reduction to synthesize 1-(4-aminophenyl)-4-(4-hydroxyphenyl) piperazine with the purity of 98A% and the correction yield of 77%; and finally, synthesizing 4-[4-[4-(4-hydroxyphenyl) piperazine-1-yl] phenyl] phenyl carbamate with the purity of 98.7%, the content of 98.5 wt% and the correction yield of 83% by using phenyl chloroformate to protect phenolic hydroxyl groups. According to the invention, the high-purity target product 4-[4-[4-(4-hydroxyphenyl) piperazine-1-yl] phenyl] phenyl carbamate can be obtained through easily available raw materials and simple process steps.

Antifungal water-soluble compound as well as preparation method and application thereof (by machine translation)

The invention provides an antifungal water-soluble compound, a preparation method thereof and application, of the compound as I shown in formula. The compound has good antifungal effect and water solubility, can be used for treating and preventing,configuration optical isomers of the optical isomer SRSS obtained by chiral synthesis. (by machine translation)

Synthesis, Crystal Structure, Anti-Bone Cancer Activity and Molecular Docking Investigations of the Heterocyclic Compound 1-((2S,3S)-2-(Benzyloxy)Pentan-3-yl) -4-(4-(4-(4-Hydroxyphenyl)Piperazin-1-yl) Phenyl)-1H-1,2,4-Triazol-5(4H)-One

Heterocyclic compound 1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (1) designed using 4-(4-(4-aminophenyl)piperazin-1-yl)phenol (2) and (S)-N′-(2-(benzyloxy)propylidene)formohydrazide (3) as start materials is successfully obtained via a multistep synthesis and finally characterized by IR, 1H NMR, and single crystal X-ray diffraction. In addition, the in vitro anticancer activities of newly synthesized compound 1 are evaluated against three human bone cancer cell lines U2OS, Saos-2, and GC9811. In addition, the molecular docking is used to study the potential antiviral activity of 1 by calculating the binding sites for the 1AS0 protein.

Preparation method of posaconazole

The invention discloses a preparation method of posaconazole. The preparation method of the posaconazole provided by the invention comprises the following steps: in the presence of inorganic protonic acid, performing hydrolysis reaction on a compound II to obtain posaconazole I. The preparation method provided by the invention is easy and safe to operate, does not need any special equipment, is free from heavy metal residues, produces less reaction side products, and has high yield; a prepared product has high purity (chiral purity is larger than 99.90 percent, related substance purity is larger than 99.50 percent, all impurities are less than 0.1 percent, and raw materials meet the standard), is low in production cost, is environmentally friendly, and is suitable for industrial production. The formula of the posaconazole is shown in the description.

Process for the Preparation of Triazole Antifungal Drug, Its Intermediates and Polymorphs Thereof

A process for the preparation of 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one compound of formula-1, its intermediates and polymorphs thereof. (I)